Clinical Study On The Improvement Of Life Quality And Prognosis Of Patients With Primary Hepatic Carcinoma After TACE By Fuyang Yigan Decoction

Objective: To observe the effects of Fuyang Yigan Decoction on the quality of life and short-term prognosis of patients with primary hepatic carcinoma after Transcatheter Arterial Chemoembolization(TACE).Methods: A total of 80 patients with primary hepatic carcinoma who met the inclusion criteria after TACE surgery were collected and randomly divided into the experimental group and the control group,with 40 cases in each group.The control group was treated with TACE,and the experimental group was treated with Fuyang Yigan Decoction on the basis of the control group.Both groups were treated for 12 weeks and followed up for half a year.To observe the changes of Karnofsky score,Traditional Chinese Medicine(TCM)symptom score,solid tumor size,alpha fetoprotein(AFP),coagulation function(PT),alanine transaminase(ALT),aspartate transaminase(AST),serum total bilirubin(TBi L)and serum albumin(ALB)in the two groups after treatment,And evaluate the Fuyang Yigan Decoction on the quality of life,recurrence rate,mortality and the safety indexes with primary hepatic carcinoma after TACE.Results:(1)the recurrence rate(25% vs 47.5%,P<0.05)and the mortality rate(20% vs 42.5%,P<0.05)of the experimental group were significantly lower than the control group within 6 months of follow-up.(2)in terms of quality of life: after 4 weeks and 12 weeks of treatment,Karnofsky score and TCM syndrome score in the experimental group were significantly improved compared with the control group(P<0.05).(3)solid tumor size and laboratory indicators: after 4 weeks of treatment,ALT and AST levels in the experimental group were significantly lower than those in the control group(P<0.05),while there was no significant difference in solid tumor size,AFP,PT,TBi L and ALB levels between the two groups(P>0.05).After 12 weeks of treatment,the tumor size,AFP level and ALB level of the experimental group were all better than those of the control group(P<0.05),while there was no significant difference in PT,ALT,AST and TBi L levels between the two groups(P>0.05).(4)safety: no obvious abnormalities of hematuria routine,renal function and electrocardiogram were observed before and after treatment in the two groups,and no serious adverse events occurred;Compared with the control group,the experimental group had fewer cases of uncomfortable symptoms,indicating that Fuyang Yigan Decoction was safer.Conclutions: Fuyang Yigan Decoction can improve the quality of life of patients with primary hepatic carcinoma after TACE,reduce the recurrence rate and mortality within half a year,reduce the tumor lesions,delay the disease progression,and improve the overall clinical efficacy without obvious toxic and side effects and has a good safety.